Similar Clinical Benefits from Below-Target and Target Dose Enalapril in Patients with Heart Failure in the SOLVD Treatment Trial

Authors

Phillip H. Lam
Gregg C. Fonarow
Javed Butler
Michel White
Wilbert S. Aronow, New York Medical CollegeFollow
Bertram Pitt
Ali AhmedFollow

DOI

10.1002/ejhf.937

Journal Title

European Journal of Heart Failure

First Page

359

Last Page

369

Document Type

Article

Publication Date

2-1-2018

Department

Medicine

Abstract

AIMS: To examine associations of below-target and target dose of enalapril, an angiotensin-converting enzyme (ACE) inhibitor, with outcomes in patients with heart failure and reduced ejection fraction (HFrEF) in the Studies of Left Ventricular Dysfunction (SOLVD) Treatment trial. METHODS AND RESULTS: Two thousand five hundred and sixty-nine patients with HFrEF (ejection fraction

Recommended Citation

Lam, P. H., Fonarow, G., Butler, J., White, M., Aronow, W., Pitt, B., & Ahmed, A. (2018). Similar Clinical Benefits from Below-Target and Target Dose Enalapril in Patients with Heart Failure in the SOLVD Treatment Trial. European Journal of Heart Failure, 20 (2), 359-369. https://doi.org/10.1002/ejhf.937